NCT06041763 Bridge-Enhanced ACL Repair (BEAR) in Meniscus Repair
| NCT ID | NCT06041763 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Meniscus Tear |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-11-20 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2024-11-20 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The bridge-enhanced ACL repair (BEAR) implant is a collagen-based scaffold loaded with whole blood. It is designed to promote healing in the setting of intraarticular knee pathology. This study would compare clinical outcomes and synovial fluid cytokine profiles in patients who undergo isolated meniscal repair with or without the BEAR implant.
Eligibility Criteria
Inclusion Criteria: • History of meniscus injury indicated for isolated repair, without concomitant ligament reconstruction or repair, cartilage repair procedure, or osteotomy. Exclusion Criteria: * Patients who are undergoing meniscal repair for displaced bucket-handle meniscal tears * Patients with a history of blood-borne diseases including HIV, hepatitis B virus, hepatitis C virus, human T-lymphotropic virus, and syphilis
Contact & Investigator
Guillem Gonzalez-Lomas, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06041763 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Meniscus Tear. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06041763 currently recruiting?
Yes, NCT06041763 is actively recruiting participants. Contact the research team at Emma.trasatti@nyulangone.org for enrollment information.
Where is the NCT06041763 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06041763 clinical trial?
NCT06041763 is sponsored by NYU Langone Health. The principal investigator is Guillem Gonzalez-Lomas, MD at NYU Langone Health. The trial plans to enroll 80 participants.